Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
Holding JAZZ?
Track your performance easily
JAZZ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$99.06 - $137.39
Previous Close$109.57
Volume974.44K
Average Volume (3M)696.29K
Market Cap
$6.77B
Enterprise Value$11.18B
Total Cash (Recent Filing)$1.36B
Total Debt (Recent Filing)$5.77B
Price to Earnings (P/E)19.6
Beta0.61
Next Earnings
Nov 05, 2024EPS Estimate
$5.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.60
Shares Outstanding61,753,510
10 Day Avg. Volume650,839
30 Day Avg. Volume696,287
Standard Deviation0.09
R-Squared0.12
Alpha-0.00512
Financial Highlights & Ratios
Price to Book (P/B)1.80
Price to Sales (P/S)1.76
Price to Cash Flow (P/CF)5.20
P/FCF Ratio5.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.86
Enterprise Value/Gross Profit3.29
Enterprise Value/Ebitda13.66
Forecast
1Y Price Target
$174.38Price Target Upside56.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Jazz Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe updated Phase 2 data for zani plus chemo in first-line GEA demonstrated an improved ORR of 84% and mPFS of 15.2 months, supporting further development.
Financial PerformanceStrong quarter of revenue for Epidiolex, as second quarter sales of $247 million were 22% higher than the same period last year.
Growth PotentialJazz Pharmaceuticals highlighted their confidence in the opportunity for Zanidatamab in post-Enhertu breast cancer.
Bears Say
Clinical TrialsJazz updated that its Ph2b trial evaluating JZP-385 as a treatment for essential tremor failed to reach statistical significance on its primary study endpoint.
EarningsExpect a slight downtick in JAZZ based on the slightly lowered topline guidance for FY 2024.
Market CompetitionThe narcolepsy market is more mature and has seen less growth overall due to competition from authorized generics and branded fixed dose products.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
JAZZ FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $99.06 and its highest was $137.38 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Currently, no data Available
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Nov 05, 2024 which is in 46 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Jul 31, 2024. The company reported $5.3 earnings per share for the quarter, beating the consensus estimate of $4.922 by $0.378.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is $5.53.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 61,753,510 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of $5.3 in its last earnings report, beating expectations of $4.922. Following the earnings report the stock price went up 3.746%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Among the largest hedge funds holding Jazz Pharmaceuticals’s share is Polaris Capital Management LLC. It holds Jazz Pharmaceuticals’s shares valued at 147M.
---
Jazz Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$174.38 (56.69% Upside)
$174.38 (56.69% Upside)
Blogger Sentiment
Bullish
JAZZ Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 396.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $152.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.22%
12-Months-Change
Fundamentals
Return on Equity
10.84%
Trailing 12-Months
Asset Growth
0.90%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
---
JAZZ Company Deck
---
JAZZ Earnings Call
Q2 2024
0:00 / 0:00
---
JAZZ Stock 12 Month Forecast
Average Price Target
$174.38
▲(56.69% Upside)
Technical Analysis
Best Analysts Covering JAZZ
1 Year
1 Year Success Rate
13/24 ratings generated profit
1 Year Average Return
+2.70%
reiterated a buy rating 9 days ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 54.17% of your transactions generating a profit, with an average return of +2.70% per trade.
---